Avibactam Sodium
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Avibactam Sodium
- Avibactam Sodium: Repurposing Evaluation Inconclusive — No TxGNN Predictions Available
Avibactam Sodium: Repurposing Evaluation Inconclusive — No TxGNN Predictions Available
One-Sentence Summary
Avibactam Sodium is a non-β-lactam β-lactamase inhibitor, used in combination with ceftazidime to treat serious gram-negative bacterial infections. The TxGNN model did not generate any repurposing predictions for this compound in the current evidence pack, and no Finland regulatory authorizations are on file. A formal repurposing evaluation cannot be conducted at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gram-negative bacterial infections (combination partner of ceftazidime; evidence from external domain knowledge — not present in evidence pack) |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — no predictions generated |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why No Prediction is Available
Avibactam Sodium is a β-lactamase inhibitor without intrinsic antibacterial activity. Its sole mechanism of action is irreversible, covalent binding to serine β-lactamases (class A, C, and some class D enzymes), thereby shielding its combination partner (ceftazidime) from enzymatic inactivation. This highly specific, adjunctive mechanistic role — rather than a direct receptor-mediated or pathway-level effect — may limit TxGNN's ability to identify disease-graph associations for the compound as a standalone node.
Additionally, the evidence pack confirms no DrugBank ID was resolved (drugbank_id: null) and no original indications were populated. The absence of a mapped knowledge graph node is the most likely technical reason no predictions were returned.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence pack contains no TxGNN repurposing predictions, no Finland regulatory authorizations, and no safety data. There is no evidentiary basis on which to proceed with a repurposing evaluation.
To proceed, the following is needed:
- Resolve DrugBank ID: Confirm whether Avibactam Sodium has a DrugBank entry (it may be listed under the combination product Ceftazidime-Avibactam, DB09050) and re-map the knowledge graph node.
- Clarify evaluation scope: Determine whether the evaluation target is Avibactam Sodium as a standalone compound or the Ceftazidime-Avibactam combination — TxGNN predictions will differ significantly between the two.
- Re-run TxGNN pipeline: Once the node is correctly mapped, rerun prediction to obtain scored indication candidates.
- Retrieve package insert: Obtain warnings, contraindications, and MOA from the official Finnish/EMA-approved SmPC (Zavicefta).
- Populate original indications: Register the approved indications (complicated UTI, complicated IAI, hospital-acquired/ventilator-associated pneumonia) in the evidence pack before re-evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.